Article Text

other Versions

PDF
Lack of efficacy of etanercept in Sjögren’s syndrome correlates with failed suppression of TNFα and systemic immune activation
  1. Niki M Moutsopoulos (nmoutsop{at}mail.nih.gov)
  1. Oral Infection and Immunity Branch, NIDCR, NIH, United States
    1. Gikas E. Katsifis (katsifisg{at}yahoo.gr)
    1. Oral Infection and Immunity Branch, NIDCR, NIH, United States
      1. Nikola Angelov (nangelov{at}llu.edu)
      1. Loma Linda University, United States
        1. Rose A. Leakan (rleakan{at}dir.nidcr.nih.gov)
        1. Gene Therapy and Therapeutics Branch, NIDCR, United States
          1. Vidya Sankar
          1. Gene Therapy and Therapeutics Branch, NIDCR, United States
            1. Stanley Pillemer (pillemers{at}medimmune.com)
            1. Gene Therapy and Therapeutics Branch, NIDCR, United States
              1. Sharon M. Wahl (smwahl{at}dir.nidcr.nih.gov)
              1. Oral Infection and Immunity Branch, NIDCR, United States

                Abstract

                Objective: To provide insight into the clinical failure of the TNFα inhibitor, etanercept, in primary Sjögren’s syndrome (pSS), we perform an extensive analysis of the systemic immune profile of pSS patients and monitor the effect of etanercept treatment on these immune parameters.

                Methods: Peripheral blood mononuclear cells (PBMC) of primary SS patients and healthy controls were compared by flow cytometry for differences in distribution of specific cell populations (T cells, B cells, monocytes), as well as for their expression of activation markers (CD25, HLADR), TNF receptors and chemokine receptors (CXCR1, 2) before and after treatment. Systemic cytokine levels were measured by multiplex ELISA assay in plasma and in LPS stimulated whole blood from healthy controls and from pSS patients before and after etanercept. Baseline cytokine levels were correlated with clinical markers of disease.

                Results: Prior to treatment, salivary gland inflammatory focus scores did not correlate with circulating TNF levels. Further consistent with lack of evidence of significant clinical benefit, enhanced markers of immune activation, frequency of cell subpopulations, and aberrant cytokine profiles were not restored to normal levels by etanercept treatment. Remarkably, the levels of circulating TNFα were significantly increased after treatment.

                Conclusion: Etanercept is an ineffective therapeutic agent in pSS consistent with the absence of suppression of TNFα and other indicators of immune activation in this patient population. These data suggest that TNFα may not be a pivotal cytokine in the pathogenesis of pSS, impelling continued molecular characterization of disease parameters to define appropriate intervention targets.

                • Sjögren’s syndrome
                • TNF&[alpha]
                • etanercept

                Statistics from Altmetric.com

                Request permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.